Peres Jepchirchir provisionally suspended for EPO after sample taken before her Sydney Marathon win
केन्याई मैराथन धाविका पेरेस जेपचिरचिर को एथलेटिक्स इंटीग्रिटी यूनिट (AIU) ने अनंतिम रूप से निलंबित किया है, क्योंकि 30 अगस्त 2026 की सिडनी मैराथन से पहले केन्या में उनके दिए गए प्रतिस्पर्धा-बाहरी नमूने में EPO (एरिथ्रोपोइटिन) के लिए प्रतिकूल विश्लेषण परिणाम आया। वे 33 वर्ष की हैं और उस दौड़ को 2 घंटे 18 मिनट 31 सेकंड में जीतीं, अपनी हमवतन आयरिन चेपेत चेपताई से तीन मिनट से अधिक आगे। जेपचिरचिर 2020 टोक्यो ओलंपिक और सितंबर 2025 की विश्व चैंपियनशिप की मैराथन स्वर्ण पदक विजेता हैं, साथ ही न्यूयॉर्क 2021, बोस्टन 2022 और लंदन 2024 जीत चुकी हैं और हाफ मैराथन की विश्व रिकॉर्डधारी रही हैं। अनंतिम निलंबन अंतिम दोषसिद्धि नहीं है; बी-नमूना विश्लेषण, अनुशासनात्मक सुनवाई और अपील का रास्ता खुला है।
Lead
Olympic and world marathon champion Peres Jepchirchir has been provisionally suspended by the Athletics Integrity Unit (AIU) after an out-of-competition sample returned an adverse analytical finding for EPO (erythropoietin).
The sample was provided by the 33-year-old Kenyan before she won the Sydney Marathon on 30 August 2026, where she clocked 2:18:31 and finished more than three minutes clear of compatriot Irene Chepet Cheptai.
Key facts
- Athlete: Peres Jepchirchir, Kenya, 33, women's marathon.
- Action: Provisional suspension by the AIU.
- Cause: Adverse analytical finding for EPO in an out-of-competition sample.
- Sample: Collected in Kenya, before the Sydney Marathon of 30 August 2026.
- Race result: First place in Sydney, 2:18:31, ahead of Irene Chepet Cheptai by more than three minutes.
- Other major wins: Tokyo 2026 Olympic marathon, Tokyo 2026 World Championships marathon, New York 2026, Boston 2026, London 2026.
- Other achievement: Women's half-marathon world record in 2026, broken again on three occasions in 2026.
- Status: Provisional suspension only; no final finding has been made.
What EPO is and why it is prohibited
EPO is a natural substance produced in the kidneys that stimulates the production of new red blood cells. Red blood cells carry oxygen to the muscles, so raising their number can increase the oxygen available during sustained effort. When injected, EPO is detectable in urine or blood only for a short window, which is why out-of-competition testing and carefully timed sample collection matter so much.
Under the World Anti-Doping Agency's Prohibited List, EPO sits in the class of peptide hormones and related substances. It is treated as a non-specified substance, meaning the default sanction if a violation is established is four years, reducible if the athlete can show the violation was not intentional.
The career at stake
Jepchirchir's record is among the strongest in the modern women's marathon. She set the half-marathon world record in 2026 and lowered it three times in 2026, then moved up to the full marathon and won the Tokyo 2026 Olympic title. She returned to the same city in September 2026 to win the World Championships marathon, and added New York 2026, Boston 2026 and London 2026 to her list of major-city titles.
The Sydney race
Sydney became the seventh World Marathon Major in 2026, which raised both the quality of the field and the significance of the result. Jepchirchir's margin of more than three minutes in a race of that standard was unusually large. That the sample in question was collected before the race, rather than after it, is central to how the case is likely to be argued.
The process
A provisional suspension is an interim measure, not a final sanction. It prevents an athlete from competing while the case is resolved. The athlete is entitled to request analysis of the B sample, to access laboratory documentation, and to present evidence at a hearing. Because EPO is a non-specified substance, a provisional suspension is the normal course rather than an exceptional step.
If a violation is ultimately established, results from the relevant period can be annulled, medals withdrawn and prize money recovered. Any such decision is a matter for the disciplinary panel, and appeal routes remain open.
Broader context
Kenya has long been the centre of gravity in distance running, and its anti-doping infrastructure has been under scrutiny for years, including through World Athletics' watch-list arrangements. That context is relevant to the debate but should not be applied to an individual case, which must be decided on its own facts and on the evidence produced in the process.
What happens next
The B-sample analysis, if requested, is the immediate next step. Beyond that comes a disciplinary hearing, at which technical questions about the analytical method, the biological passport parameters and the chain of custody of the sample are likely to be central. Until that process concludes, the fair position is that the matter is unresolved.
Timeline
- 2026: Half-marathon world record.
- 2026: Record lowered on three further occasions.
- 2026 Tokyo Olympics: Marathon gold.
- 2026: New York Marathon win.
- 2026: Boston Marathon win.
- 2026: London Marathon win.
- September 2026: World Championships marathon gold in Tokyo.
- 2026: Sydney Marathon becomes the seventh World Marathon Major.
- 30 August 2026: Sydney Marathon win in 2:18:31; sample collected before the race in Kenya.
- Afterwards: Adverse analytical finding for EPO; provisional suspension by the AIU.
Bottom line
The facts currently public are that an out-of-competition sample given before the Sydney Marathon returned an adverse finding for EPO and that the AIU has imposed a provisional suspension. Everything beyond that — sanction, annulment of results, or a successful defence — depends on a disciplinary process that has only just begun.